Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$21.08 USD
-0.29 (-1.36%)
Updated Jul 17, 2024 11:42 AM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 41 - 60 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Low Street 2Q Expectations; We Don?t Expect Lowered Guide; Potential Near-Term CMS Upside; PT to $68; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1:23 Revenues Lay the Foundation for 2023; EXPAREL Growth Opportunities Ahead
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Modest Margin Hangover Spooks Street, But Guidance Reiterated and No Real Change to Our Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
First Guidance Since Pre-Pandemic Highlights Operating Leverage Growth; Reset Makes Name Easy To Own Here; PT to $71
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY22: Multiple Opportunities for Product Growth & Pipeline Progress in 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Imminent First Guidance Since Before Pandemic An Important Estimate Reset; Lower PT to $69 But Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Assuming Coverage at OP; Leading the Transition to Non- Opioid Pain Management
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preliminary FY22 Revenue; Focus Remains on Opportunities for Growth in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L